BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 30039850)

  • 1. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
    Eshun-Wilson I; Okwen MP; Richardson M; Bicanic T
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009012. PubMed ID: 30039850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis.
    Njei B; Kongnyuy EJ; Kumar S; Okwen MP; Sankar MJ; Mbuagbaw L
    Cochrane Database Syst Rev; 2013 Feb; (2):CD009012. PubMed ID: 23450595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for HIV-associated cryptococcal meningitis.
    Tenforde MW; Shapiro AE; Rouse B; Jarvis JN; Li T; Eshun-Wilson I; Ford N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD005647. PubMed ID: 30045416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people.
    Awotiwon AA; Johnson S; Rutherford GW; Meintjes G; Eshun-Wilson I
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD004773. PubMed ID: 30156270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid initiation of antiretroviral therapy for people living with HIV.
    Mateo-Urdiales A; Johnson S; Smith R; Nachega JB; Eshun-Wilson I
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD012962. PubMed ID: 31206168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating progressive disseminated histoplasmosis in people living with HIV.
    Murray M; Hine P
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD013594. PubMed ID: 32343003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
    Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.
    Onwumeh J; Okwundu CI; Kredo T
    Cochrane Database Syst Rev; 2017 May; 5(5):CD009818. PubMed ID: 28542796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micronutrient supplementation in adults with HIV infection.
    Visser ME; Durao S; Sinclair D; Irlam JH; Siegfried N
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003650. PubMed ID: 28518221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral resistance testing in HIV-positive people.
    Aves T; Tambe J; Siemieniuk RA; Mbuagbaw L
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD006495. PubMed ID: 30411789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
    Jarvis JN; Lawrence DS; Meya DB; Kagimu E; Kasibante J; Mpoza E; Rutakingirwa MK; Ssebambulidde K; Tugume L; Rhein J; Boulware DR; Mwandumba HC; Moyo M; Mzinganjira H; Kanyama C; Hosseinipour MC; Chawinga C; Meintjes G; Schutz C; Comins K; Singh A; Muzoora C; Jjunju S; Nuwagira E; Mosepele M; Leeme T; Siamisang K; Ndhlovu CE; Hlupeni A; Mutata C; van Widenfelt E; Chen T; Wang D; Hope W; Boyer-Chammard T; Loyse A; Molloy SF; Youssouf N; Lortholary O; Lalloo DG; Jaffar S; Harrison TS;
    N Engl J Med; 2022 Mar; 386(12):1109-1120. PubMed ID: 35320642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
    Cortegiani A; Russotto V; Maggiore A; Attanasio M; Naro AR; Raineri SM; Giarratano A
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD004920. PubMed ID: 26772902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa.
    Makadzange AT; Ndhlovu CE; Takarinda K; Reid M; Kurangwa M; Gona P; Hakim JG
    Clin Infect Dis; 2010 Jun; 50(11):1532-8. PubMed ID: 20415574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV.
    Chang LW; Phipps WT; Kennedy GE; Rutherford GW
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004773. PubMed ID: 16034947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children.
    Pienaar ED; Young T; Holmes H
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD003940. PubMed ID: 21069679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
    Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
    Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
    Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M
    Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.